Radiofrequency ablation and chemoembolization for hepatocellular carcinoma

Christos S Georgiades, Kelvin Hong, Jean Francois Geschwind

Research output: Contribution to journalArticle

Abstract

Purpose: To provide an up-to-date review of the technique, efficacy, safety and clinical applications for radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). Methods: A thorough review of the literature was performed as related to RFA and TACE for the treatment of HCC. We mixed these findings with our own extensive research and clinical experience on this subject by drawing from a pool of more than 1000 patients treated with both modalities. Results: TACE has been shown with the work of Llovet, Camma, and Lo to provide a significant survival benefit for patients with unresectable HCC. The former showed a 1-, 2-, and 3-year survival at 57%, 31%, and 26% in the treatment group vs. 32%, 11%, and 3% in the supportive treatment alone group, respectively. Repeatedly, RFA has been shown to be very effective in the treatment of small (ĝ‰Currency sign3 cm) HCC lesions with a complete response rate of about 90%. Studies have shown that RFA may be equivalent to surgical resection in this subgroup of patients. For both modalities, patient selection and proper technique are important in minimizing the possible complications associated with them, which rarely includes liver failure, abscess formation, and hemorrhage. Discussion: RFA and TACE have both been shown to provide a survival benefit for patients with unresectable HCC. More recent studies have paired these modalities with surgical resection with favorable results. Refined technique, improvements in technology, and research on better-targeted chemotherapy will likely result in further improved survival benefit. Additionally, the scope of this treatment is broadening to include resectable patients, patients awaiting liver transplantation, and, in combination with other systemic (bevacizumab, sorafenib, etc) or locoregional (RFA-TACE combination, RFA-resection etc) treatments.

Original languageEnglish (US)
Pages (from-to)117-122
Number of pages6
JournalCancer Journal
Volume14
Issue number2
DOIs
StatePublished - Mar 2008

Fingerprint

Hepatocellular Carcinoma
Survival
Therapeutics
Liver Abscess
Liver Failure
Research
Liver Transplantation
Patient Selection
Hemorrhage
Technology
Safety
Drug Therapy

Keywords

  • Hepatocellular carcinoma
  • Radiofrequency ablation
  • Transarterial chemoembolization

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Radiofrequency ablation and chemoembolization for hepatocellular carcinoma. / Georgiades, Christos S; Hong, Kelvin; Geschwind, Jean Francois.

In: Cancer Journal, Vol. 14, No. 2, 03.2008, p. 117-122.

Research output: Contribution to journalArticle

@article{4e9aa1709240401485d254ca4a9e96e8,
title = "Radiofrequency ablation and chemoembolization for hepatocellular carcinoma",
abstract = "Purpose: To provide an up-to-date review of the technique, efficacy, safety and clinical applications for radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). Methods: A thorough review of the literature was performed as related to RFA and TACE for the treatment of HCC. We mixed these findings with our own extensive research and clinical experience on this subject by drawing from a pool of more than 1000 patients treated with both modalities. Results: TACE has been shown with the work of Llovet, Camma, and Lo to provide a significant survival benefit for patients with unresectable HCC. The former showed a 1-, 2-, and 3-year survival at 57{\%}, 31{\%}, and 26{\%} in the treatment group vs. 32{\%}, 11{\%}, and 3{\%} in the supportive treatment alone group, respectively. Repeatedly, RFA has been shown to be very effective in the treatment of small (ĝ‰Currency sign3 cm) HCC lesions with a complete response rate of about 90{\%}. Studies have shown that RFA may be equivalent to surgical resection in this subgroup of patients. For both modalities, patient selection and proper technique are important in minimizing the possible complications associated with them, which rarely includes liver failure, abscess formation, and hemorrhage. Discussion: RFA and TACE have both been shown to provide a survival benefit for patients with unresectable HCC. More recent studies have paired these modalities with surgical resection with favorable results. Refined technique, improvements in technology, and research on better-targeted chemotherapy will likely result in further improved survival benefit. Additionally, the scope of this treatment is broadening to include resectable patients, patients awaiting liver transplantation, and, in combination with other systemic (bevacizumab, sorafenib, etc) or locoregional (RFA-TACE combination, RFA-resection etc) treatments.",
keywords = "Hepatocellular carcinoma, Radiofrequency ablation, Transarterial chemoembolization",
author = "Georgiades, {Christos S} and Kelvin Hong and Geschwind, {Jean Francois}",
year = "2008",
month = "3",
doi = "10.1097/PPO.0b013e31816a0fac",
language = "English (US)",
volume = "14",
pages = "117--122",
journal = "Cancer journal (Sudbury, Mass.)",
issn = "0765-7846",
publisher = "Association Pour le Developpement de la Communication Cancerologique",
number = "2",

}

TY - JOUR

T1 - Radiofrequency ablation and chemoembolization for hepatocellular carcinoma

AU - Georgiades, Christos S

AU - Hong, Kelvin

AU - Geschwind, Jean Francois

PY - 2008/3

Y1 - 2008/3

N2 - Purpose: To provide an up-to-date review of the technique, efficacy, safety and clinical applications for radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). Methods: A thorough review of the literature was performed as related to RFA and TACE for the treatment of HCC. We mixed these findings with our own extensive research and clinical experience on this subject by drawing from a pool of more than 1000 patients treated with both modalities. Results: TACE has been shown with the work of Llovet, Camma, and Lo to provide a significant survival benefit for patients with unresectable HCC. The former showed a 1-, 2-, and 3-year survival at 57%, 31%, and 26% in the treatment group vs. 32%, 11%, and 3% in the supportive treatment alone group, respectively. Repeatedly, RFA has been shown to be very effective in the treatment of small (ĝ‰Currency sign3 cm) HCC lesions with a complete response rate of about 90%. Studies have shown that RFA may be equivalent to surgical resection in this subgroup of patients. For both modalities, patient selection and proper technique are important in minimizing the possible complications associated with them, which rarely includes liver failure, abscess formation, and hemorrhage. Discussion: RFA and TACE have both been shown to provide a survival benefit for patients with unresectable HCC. More recent studies have paired these modalities with surgical resection with favorable results. Refined technique, improvements in technology, and research on better-targeted chemotherapy will likely result in further improved survival benefit. Additionally, the scope of this treatment is broadening to include resectable patients, patients awaiting liver transplantation, and, in combination with other systemic (bevacizumab, sorafenib, etc) or locoregional (RFA-TACE combination, RFA-resection etc) treatments.

AB - Purpose: To provide an up-to-date review of the technique, efficacy, safety and clinical applications for radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) for hepatocellular carcinoma (HCC). Methods: A thorough review of the literature was performed as related to RFA and TACE for the treatment of HCC. We mixed these findings with our own extensive research and clinical experience on this subject by drawing from a pool of more than 1000 patients treated with both modalities. Results: TACE has been shown with the work of Llovet, Camma, and Lo to provide a significant survival benefit for patients with unresectable HCC. The former showed a 1-, 2-, and 3-year survival at 57%, 31%, and 26% in the treatment group vs. 32%, 11%, and 3% in the supportive treatment alone group, respectively. Repeatedly, RFA has been shown to be very effective in the treatment of small (ĝ‰Currency sign3 cm) HCC lesions with a complete response rate of about 90%. Studies have shown that RFA may be equivalent to surgical resection in this subgroup of patients. For both modalities, patient selection and proper technique are important in minimizing the possible complications associated with them, which rarely includes liver failure, abscess formation, and hemorrhage. Discussion: RFA and TACE have both been shown to provide a survival benefit for patients with unresectable HCC. More recent studies have paired these modalities with surgical resection with favorable results. Refined technique, improvements in technology, and research on better-targeted chemotherapy will likely result in further improved survival benefit. Additionally, the scope of this treatment is broadening to include resectable patients, patients awaiting liver transplantation, and, in combination with other systemic (bevacizumab, sorafenib, etc) or locoregional (RFA-TACE combination, RFA-resection etc) treatments.

KW - Hepatocellular carcinoma

KW - Radiofrequency ablation

KW - Transarterial chemoembolization

UR - http://www.scopus.com/inward/record.url?scp=50949120748&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50949120748&partnerID=8YFLogxK

U2 - 10.1097/PPO.0b013e31816a0fac

DO - 10.1097/PPO.0b013e31816a0fac

M3 - Article

C2 - 18391617

AN - SCOPUS:50949120748

VL - 14

SP - 117

EP - 122

JO - Cancer journal (Sudbury, Mass.)

JF - Cancer journal (Sudbury, Mass.)

SN - 0765-7846

IS - 2

ER -